Skip to main content
NCBI home page
Evidence-based Complementary and Alternative Medicine : eCAM logoLink to Evidence-based Complementary and Alternative Medicine : eCAM
. 2015 Jan 12;2015:459749. doi: 10.1155/2015/459749

Liver Damage Associated with Polygonum multiflorum Thunb.: A Systematic Review of Case Reports and Case Series

Xiang Lei 1, Jing Chen 1, Jingtian Ren 2, Yan Li 1, Jingbo Zhai 1, Wei Mu 3, Li Zhang 3, Wenke Zheng 1, Guihua Tian 4, Hongcai Shang 1,5,*
PMCID: PMC4306360  PMID: 25648693

Abstract

Objective. To summarize the characteristics and analysis of relevant factors and to give references for prevention and further study of liver damage associated with Polygonum multiflorum Thunb. (HSW), we provide a systematic review of case reports and case series about liver damage associated with HSW. Methods. An extensive search of 6 medical databases was performed up to June 2014. Case reports and case series involving liver damage associated with HSW were included. Results. This review covers a total of 450 cases in 76 articles. HSW types included raw and processed HSW decoction pieces and many Chinese patent medicines that contain HSW. Symptoms of liver damage occur mostly a month or so after taking the medicine, mainly including jaundice, fatigue, anorexia, and yellow or tawny urine. Of the 450 patients, two cases who received liver transplantation and seven who died, the remaining 441 cases recovered or had liver function improvement after discontinuing HSW products and conservative care. Conclusion. HSW causes liver toxicity and may cause liver damage in different degrees and even lead to death; most of them are much related to long-term and overdose of drugs. Liver damage associated with HSW is reversible, and, after active treatment, the majority can be cured. People should be alert to liver damage when taking HSW preparations.

1. Introduction

Polygonum multiflorum Thunb. (He Shou Wu in Chinese pinyin, hereinafter referred to as HSW) is the root of Polygonum multiflorum, a member of Polygonaceae. As a Chinese herb, it was recorded most early in “Kaibao Bencao” published by the imperial court of the Song Dynasty (973-974 A.D.) [1]. In the Chinese Pharmacopoeia (2010), there are two forms of HSW decoction pieces: raw state (natural root) (Figure 1) and processed form, that is, radix polygoni multiflori preparata (boiled in black-bean liquid according to a traditional process) (Figure 2). The two forms have different properties: the raw HSW is used for detoxification, eliminating carbuncle, preventing malaria, and relaxing bowel, whereas the processed HSW is used for nourishing liver and kidney, supplementing essence and blood, blackening hair, strengthening bones and muscles, eliminating dampness, and reducing lipid [2]. Modern pharmacological studies have shown that HSW have the effect of reducing blood lipid and antiarteriosclerosis [3–5], protecting liver [6, 7], enhancing immunologic [8, 9], improving memory, protecting nerve cells, and increasing intelligence [10, 11], antioxidation, antiaging [12, 13], and so forth.

Figure 1.

Figure 1

Open in a new tab

Raw HSW.

Figure 2.

Figure 2

Open in a new tab

Processed HSW.

HSW is popular in many countries, especially in China. Traditional Chinese herbal medicine ordinarily recommends the use of herbs in complex formulas, but HSW is also often taken as a single herb. While there are many HSW-containing products, the most well-known product is like Shou-Wu-Pian, which is usually consumed as an antiaging product, or as a tonic for dizziness with tinnitus, and also appears to be efficacious in the treatment of premature greying of hair, lumbago, spermatorrhea, leucorrhea, and constipation. With the wide application, liver damage associated with HSW has been reported in China, Korea, Japan, Britain, Italy, Australia, and other countries [14, 15]. To fully understand the characteristics and possible factors of hepatitis associated with HSW, we conduct a comprehensive review of the relevant published literatures; we hope that our findings can provide guidance for clinical medication and scientific research and thus can help to avoid hepatitis induced by HSW in the future.

2. Methods

2.1. Data Sources and Search Strategy

In June 2014, we searched the following Chinese-language electronic databases: Chinese Biomedical Literature Database (CBM, 1980–2014), Chinese Journal Full-Text Database (CNKI, 1980–2014), Weipu Journal Database (VIP, 1989–2014), and Wanfang Data (1990–2014) and two English-language databases PubMed and EMBASE (1989–2014). The search terms included Polygonum multiflorum, radix polygoni multiflori, He Shou Wu, liver injury, liver damage, liver diseases, hepatitis, and liver failure in English or Chinese. These terms were searched as free-text in the title or the abstract. The references of relevant reviews and the included literatures were checked for possible identification of additional studies.

2.2. Study Selection

Case reports and case series are included in the review if they reported factual data on liver damage related to HSW. Clinical trials, reviews, commentaries, and other nonrelated literatures were excluded. Some clinical trials of HSW that reported liver damage were excluded for reasons originally given by Lao et al., specifically that they were too small to provide convincing evidence of rare complications [16]. Two authors (Xiang Lei and Jing Chen) independently examined the titles and abstracts of all papers found through the search to determine if they fulfilled the inclusion criteria outlined above. The full texts of potentially relevant articles were retrieved for detailed assessment. Differences can be resolved through discussion.

2.3. Data Extraction

After screening, articles were read in full and extracted by two independent reviewers (Xiang Lei and Jing Chen). Information on author, year of publication, number of patients, disease originally treated, gender, dose and dosage forms, course of taking HSW, clinical manifestations, length of hospitalization, outcome and family history, and recurrence of hepatitis related to HSW were extracted according to the designed data extraction table independently by two authors.

3. Results

3.1. Search Process and Result

The search identified 923 database records, which led to the retrieval of documentation on 103 studies for a full-text review. One additional reference was identified while searching reference lists of the included papers. 76 articles (59 case reports and 17 case series) met the inclusion criteria. In total, 450 cases of hepatitis associated with HSW were reported. The characteristics of the case reports and case series are shown in Tables 1 and 2. Because case series is summary report for multiple patients and because of the lack of description of the individual patient information, the following is mainly an analysis of case reports.

Table 1.

Patient details recorded from published case reports.

Reference Age/gender Reasons for medication HSW type Administration and dosage Duration of intake, day Hospitalization, day Outcome Rechallenge?
Liu et al. [17] 20/F Grey hair HSW OAP, 15 g 42 10 Recovery NA
Miao and Yun [18] 52/F Health care P. HSW OAP, 5 g 20 14 Recovery NA
61/F Hyperlipidemia R. HSW SIW, 5 g 180 12 Recovery NA
Zhao [19] 39/M Grey hair Jing-Wu-Pian Oral, 3 × 6 tablets 60 18 Recovery NA
Tan [20] 48/F NA P. HSW uNA, 10 g 40 30 Recovery NA
Liu et al. [21] 37/M Vitiligo P. HSW OAP, 10 g 30 35 Recovery NA
Gao et al. [22] 14/F Vitiligo P. HSW Decoction, NA 38 15 Recovery NA
Baňárová et al. [23] 33/F NA SWW Oral, NA 60 NA Recovery NA
Gao [24] 45/M Hair loss P. HSW OAP, NA 90 21 Recovery NA
Kui and Chen [25] 43/F Grey hair HSW OAP, 8–10 g 60 30 Recovery NA
Shao and Li [26] 50/M Grey hair HSW OAP, NA 60 30 Recovery NA
40/F Health care R. HSW Decoction, 10–20 g 60 50 Recovery NA
Hu et al. [27] 36/M Chronic nephritis P. HSW OAP, 15 g 30 37 Recovery NA
Zhen and Zeng [28] 52/F Grey hair P. HSW OAP, NA 14 30 Recovery NA
Li and Zhang [29] 50/F Grey hair R. HSW OAP, 2 g 60 15 Recovery NA
28/F Hair loss R. HSW OAP, 3 g 75 12 Recovery NA
Chen et al. [30] 57/M Grey hair R. HSW NA 1 20 Recovery NA
Liu et al. [31] 56/F Grey hair Yishen wufa Oral, 2 × 10 mL 120 21 Recovery NA
Sun [32] 39/F Allergic rhinitis R. HSW Decoction, 15–20 g 30 28 Recovery NA
72/F Health care R. HSW Decoction, 10–20 g 60 42 Recovery NA
Cao et al. [33] 28/M Grey hair P. HSW NA, 10 pieces 90 42 Recovery NA
Liu et al. [34] 26/M Hair loss Yangxue shengfa Oral, 2 × 4 capsules 60 30 Recovery NA
Yan [35] 28/M Hair loss HSW Decoction, 4 g 90 28 Recovery NA
Wu and Niu [36] 47/F Hair loss Yishen wufa Oral, 3 × 10 ml 20 14 Recovery NA
Liu et al. [37] 50/F Hair loss SWW Oral, NA 7 25 Recovery NA
Chen et al. [38] 46/F Health care HSW tea Oral, 1-2 g 60 25 Recovery NA
57/M Health care HSW tea Oral, 1-2 g 20 15 Recovery NA
Yun et al. [39] 51/F Grey hair SWW Oral, 2 × 6 g 180 18 Recovery NA
Furukawa et al. [40] 53/F NA SWP NA 240 60 Recovery NA
Yan et al. [41] 54/F Grey hair HSW OAP, 2 × 10 g 60 35 Recovery NA
He [42] 31/F Constipation HSW Oral, NA 15 10 Recovery NA
Chen [43] 38/F Grey hair HSW OAP, NA 120 63 Recovery NA
Cho et al. [44] 34/M NA HSW HSW tea (liquor), NA 30 (4) 34 improved NA
Wang et al. [45] 34/M Health care R. HSW SIW, NA 20 20 Recovery NA
46/M Health care R. HSW SIW, NA 10 27 Recovery NA
49/F Health care R. HSW SIW, NA 5 27 Recovery NA
Zhu [46] 36/M Hair loss R. HSW SIW, NA 30 30 Recovery NA
Yang and Li [47] 38/M Grey hair HSW Decoction, 30 g Once a week (3w) NA Recovery NA
51/M Sequelae of stroke HSW Decoction, 15 g 15 NA Recovery NA
Laird et al. [48] 35/M Thinning hair NuHair Oral, NA NA 120 Recovery NA
Yang and Dong [49] 54/M Hair loss SWP Oral, 3 × 6 tablets 40 17 Recovery NA
26/M Grey hair SWP Oral, 3 × 6 tablets 30 59 Recovery Yes
Fu and Yu [50] 32/F Infertility P. HSW Decoction, NA 18 Untreated Recovery NA
Zhao [51] 17/M Grey hair SWW Oral, 3 × 6 tablets 40 90 Recovery Yes
Li [52] 65/M Dizziness, tinnitus HSW SIW, 30–50 ml 20 30 Recovery Yes
38/M Grey hair SWP Oral, 3 × 6 tablets 30 20 Recovery NA
Cárdenas et al. [53] 28/F Hair loss Shen-Min Oral, 2 tablets 56 6 Recovery NA
Han [54] 42/F Grey hair HSW OAP, 10 g 90 30 Recovery Yes
Yang [55] 35/M Grey hair P. HSW Decoction, 30 g 45 50 Recovery NA
Panis et al. [56] 5/F NA SWP Oral, 3 tablets 120 30 Recovery Yes
Chen et al. [57] 20/F Grey hair HSW OAP, NA 20 40 Recovery NA
Huo and Ling [58] 28/M Hair loss SWP + Yangxue shengfa Oral, 3 × 5 tablets and 2 × 4 capsules 60 18 Recovery Yes
Mazzanti et al. [59] 78/M Chronic prostatitis SWP Oral, RD 30 NA Recovery NA
Shao [60] 46/F Hair loss R. HSW Decoction, NA 6 30 Recovery Yes
45/M Grey hair, hair loss R. HSW Decoction, 100 g NA 30 Recovery Yes
Leng [61] 15/F Grey hair HSW Decoction, 15 g 30 NA Recovery NA
Dai and Li [62] 18/F Grey hair SWP Oral, NA 90 90 Recovery NA
Yuan [63] 66/F Constipation HSW ointment Oral, NA 7 30 Recovery Yes
Sun [64] 20/F Neurasthenia SWP + Liuwei Dihuang Wan Oral, 3 × 6 tablets and 2 × 9 g 3 10 Recovery Yes
Yang [65] 17/M Grey hair SWP Oral, NA 14 29 Recovery Yes
Park et al. [66] 46/F Grey hair SWP Oral, RD 14 30 Recovery NA
Sheng [67] 38/F Grey hair HSW Oral, NA 6 NA Recovery Yes
Li et al. [68] 58/F Dizziness HSW Decoction, 30 g 7 15 Recovery Yes
49/M Hypertension HSW SIW, 15 g 10 20 Recovery Yes
Fan and Zhou [69] 26/M Grey hair SWP Oral, 3 × 6 tablets 30 59 Recovery Yes
Li [70] 17/M Grey hair SWP Oral, 3 × 5 tablets 20 60 Recovery Yes
Ye [71] 30/M Grey hair HSW Decoction, 50 g 2 94 Recovery Yes
Zhang [72] 36/F NA SWP Oral, 10 ml 15 15 Recovery Yes
Niu [73] 28/M Grey hair SWP Oral, 3 × 5 tablets 10 60 Recovery Yes
He and Zhen [74] 19/F Grey hair SWP Oral, NA NA 30 Recovery Yes
27/F Grey hair SWP Oral, NA NA NA Recovery Yes
But et al. [75] 31, F Dizziness SWP Oral, RD Several weeks 21 Recovery Yes
Open in a new tab

SWP: Shou-Wu-Pian; SWW: Shou-Wu-Wan; OAP: oral administration of powder; SIW: soaked in water to drink; P. HSW: processed HSW; R. HSW: raw HSW; HSW: unclear whether it was processed; RD: recommended dosages; NA: not available.

Table 2.

Characteristics of included case series.

Reference Number of cases Gender (F/M) Age (a) Duration of intake, day Type of liver injury (number) Outcome
Dong et al. [76] 18 5/13 18–63 1–120 H (18) 18 recoveries
Lian et al. [77] 52 22/30 22–69 5–120 H (30); C (9); M (13) 52 recoveries
Zhang et al. [78] 13 11/2 35–66 4–15 H (6); C (4); M (3) 12 recoveries; 1 LT
Zhang et al. [79] 36 13/23 24–73 NA H (21); C (2); M (13) 33 recoveries; 1 cirrhosis; 2 deaths
Ding [80] 65 45/20 34–71 7–90 NA 64 recoveries; 1 death
Guo [81] 15 8/7 18–57 7–56 H (8); C (3); M (4) 15 recoveries
Xie et al. [82] 10 3/7 46.1 ± 10.2 30–105 H (5); C (4); M (1); 9 recoveries; 1 death
Song [83] 26 12/14 38–71 9–93 NA 26 recoveries
Wang [84] 20 7/13 34–67 NA NA 20 recoveries
Jung et al. [85] 25 7/18 24–65 1–180 H (18); M (7) 23 recoveries; 1 LT; 1 death
Chen et al. [86] 12 5/7 20–70 15–90 H (4); C (4); M (4) 12 recoveries
Liu and Li [87] 7 5/2 31–64 60–180 NA 7 recoveries
Liu [88] 9 3/6 34–68 NA NA 9 recoveries
Xu et al. [89] 40 24/16 45.2 9–168 H (22); C (8); M (10) 38 recoveries; 2 deaths
Yang et al. [90] 13 8/5 32–68 7–30 NA 13 recoveries
Zhou and Qiu [91] 11 5/6 34–58 NA NA 11 recoveries
Zhang et al. [92] 6 3/3 24–50 4–24 w NA 6 recoveries
Open in a new tab

NA: not available; H: hepatocellular; C: cholestatic; M: mixed; LT: liver transplantation.

3.2. Gender and Age

In 450 cases, 224 (49.78%) were male and 226 (50.22%) were female. In 72 cases of case reports, patients ranged in age from 5 to 78 years, with a median of 36.5. The most commonly affected age group was 18–44 (37/72, 51.4%), followed by 45–59 (24/72, 33.3%), <18 (6/72, 8.3%), and ⩾60 (5/72, 6.9%).

3.3. Reasons for Medication (Disease Originally Treated)

In case series, the causes of consuming HSW products include grey hair, hair loss, hypertension, coronary heart disease, hyperlipidemia, osteoarthritis, insomnia, dizziness, and health care; the top diseases were gray hair and hair loss [77–91]. The reasons for medication of 72 cases of case reports are shown in Table 3.

Table 3.

Use reasons of case reports.

Disease originally treated Patients (number)
Gray hair, hair loss 43 (59.7%)
Health care 8 (11.1%)
Dizziness 3 (4.2%)
Vitiligo 2 (2.8%)
Constipation 2 (2.8%)
Othersa 8 (11.1%)
Unknown 6 (8.3%)
Total 72 (100%)
Open in a new tab

  aIncluding infertility, hypertension, allergic rhinitis, hyperlipidemia, cerebral infarction sequelae, chronic nephritis and neurasthenia, and chronic prostatitis.

3.4. Dosage Forms and Usage

In case series, there is insufficient information on HSW forms and usage of each patient, but it is worth noting that, in two case series, the ratio of processed HSW to raw HSW is 5 : 13 and 25 : 11, respectively [79, 76]. The HSW forms of case reports are shown in Table 4; in terms of usage, all involved Chinese patent medicines are of oral formulation; the types of HSW decoction pieces used included tea, liquor, powder, and decoction.

Table 4.

The classification of the drug of case reports.

Dosage forms Patients (number)
Chinese patent medicine  
 Shou-Wu-Pian 17 (23.61%)
 Shou-Wu-Wan 4 (5.56%)
 Yishen wufa 2 (2.78%)
 Othersb 5 (6.94%)
Decoction pieces  
 R. HSW 13 (18.06%)
 P. HSW 10 (13.89%)
 Unknown 21 (29.17%)
Total 72 (100%)
Open in a new tab

  bIncluding Huolisu Koufuye, Jing-Wu-Pian, NuHair, Shen-Min, and Yangxue shengfa capsules.

3.5. Dose and Duration of Taking HSW

In case series, there is insufficient information on dose and duration of taking HSW of each patient, but some articles indicate that the majority of patients take Chinese patent medicine in accordance with the instructions. For the 28 cases who consumed Chinese patent medicines in case reports, 17 (17/28, 60.7%) cases are in accordance with the recommended dosage and the remaining are unknown. Of the 44 cases who used HSW decoction pieces, 19 cases (19/44, 43.2%) did not report the daily dose; the other 25 cases' daily dose ranged from 1 to 100 g with a median of 15 g; when the daily dose was ⩽12 g (11/25), the median of duration is 30 d, but if the daily dose is >12 g (14/25), the median of duration is 60 d. For all the patients of case reports, the duration from starting to take HSW to the onset of symptoms ranged from 1 to 240 days, with a median of 30 days (Table 5).

Table 5.

The duration of taking HSW of case reports.

Duration (day) Patients (number)
<10 10 (13.89%)
10–30 27 (37.50%)
31–60 19 (26.39%)
>60 12 (16.67%)
Unknown 4 (5.56%)
Total 72 (100%)
Open in a new tab

3.6. Clinical Manifestations and Outcome

According to case reports and case series, most of the patients had been hospitalized with jaundice, fatigue, anorexia, and yellow or tawny urine. A handful of patients were found with abdominal distension, abdominal pain, diarrhea, rash, pruritus, and other symptoms. After admission examination, a few cases were found with epigastrium tenderness, first percussion over the liver, hepatomegaly or splenomegaly, and even ascites [77, 86, 89]. Nine case series reported liver damage types of 221 patients, including 132 (132/221, 59.7%) cases of hepatocytes type, 34 (34/221, 15.4%) cases of cholestatic type, and 55 (55/221, 24.9%) cases of mixed type.

In addition to two (2/450, 0.4%) cases who received liver transplantation [78, 85] and seven (7/450, 1.6%) who died [79, 89, 85–82], the remaining 441 (441/450, 98%) cases recovered or had liver function improvement after discontinuing HSW products and conservative care. In case reports, the length of 64 patients' hospitalization ranged from 6 to 120 d, with a median of 29.5 (Table 6). The case series that reported the average length of hospitalization was about four weeks [79, 91, 89, 81–92].

Table 6.

The length of hospitalization of case reports.

Hospitalization (d) Patients (number)
<15 8 (11.1%)
15–30 37 (51.4%)
31–60 14 (19.4%)
>60 5 (6.9%)
Unknown 8 (11.1%)
Total 72 (100%)
Open in a new tab

3.7. Recurrence and Family History

In case reports, 23 (23/72, 31.9%) cases were reported with liver damage associated with HSW for many times, and 3 (3/72, 4.2%) cases had family history of HSW induced hepatitis [61–71]. In case series, seven articles reported 53 (53/138, 38.4%) cases with liver damage related to HSW many times [77, 91, 82, 83–92].

4. Discussion

Based on the above information we know that HSW associated with liver injury can occur at any age group and with no gender orientation. The main reason for using HSW is that patients suffer from gray hair and hair loss; this may be associated with those patients who are more likely to use HSW products, but whether patients suffering from gray hair or hair loss are prone to occurrence of liver damage associated with HSW remains to be further studied.

Although many studies suggest that processing could reduce the toxicity of HSW [15, 93], all HSW products may lead to liver damage regardless of herbal processing. In the Chinese Pharmacopoeia (2010), predetermined daily dose of raw HSW is 3–6 g and of processed HSW is 6–12 g [2]. Although only 25 cases of case reports have the HSW dosage information, 14 cases exceed maximum dosages (12 g/d). The results show that, when daily dose is less than 12 g, from the beginning of consuming HSW to the occurrence of liver damage, the median time is 60 days, while when daily dose is more than 12 g the median time is 30 days; this suggested that HSW associated with liver damage has a “dose-time-toxicity” relationship; animal experiments also had proved it [93].

Because more than 30% of patients in case reports and cases series were reported liver damage occurred many times which was induced by HSW, and a few cases have a family history of liver damage induced by HSW; these suggested that HSW associated with liver damage may be related to personal body factors of patients.

The mechanism of HSW induced liver damage is still unclear and mainly toxic substances are also an uncertainty [15, 94]; even few animal experiments did not find hepatotoxicity of HSW [95, 96]. Some studies suggested that the adverse reactions of traditional Chinese medicine are closely related to patient self-medication, arbitrarily increase in the dose, or long-term use [97–99]; this systematic review and some papers included in it also have the same standpoint.

HSW can cause different degrees of liver injury, even need of liver transplantation (2/450), and death (6/450). However, most HSW induced liver injuries are reversible; after withdrawal of HSW products and corresponding treatments, the vast majority of patients can recover liver function.

Because HSW induced liver injury is not a specific diagnostic method and some cases included in this review also take other drugs or herbal medicines, so considering the doctors experience, medical technology, and other limiting factors may not show all liver injury is caused by HSW.

5. Conclusion

Many cases of liver damage associated with HSW had been reported worldwide; HSW has liver toxicity and may cause different degrees of liver damage. The liver damage in most patients is reversible, after discontinuation of HSW products, and active treatment can restore liver function, but there are also a small number of patients with liver failure and even death. We suggest that patients should take HSW products under the guidance of a physician or pharmacist and avoid using them for long-term or in high-dose. If fatigue, anorexia, nausea, yellowing of skin and sclera, yellow urine, and other symptoms appear after medication, patients should be alerted to the occurrence of liver damage and promptly stop the medicine and treatment.

Acknowledgment

The review was supported financially by Tianjin University Innovation Team Training Program (TD12-5032).

Conflict of Interests

The authors declare that they have no financial conflict of interests.

Authors' Contribution

Xiang Lei and Jing Chen contributed equally to this work. Hongcai Shang and Guihua Tian contributed equally to this work.

References

  • 1.Chen Q. T., Zhuo L. H., Xu W., Huang Z. H., Qiu X. H. Content changes of 5 components in Polygohum muhiflorum during processing. Chinese Journal of Experimental Traditional Medical Formulae. 2012;18(5):66–71. [Google Scholar]
  • 2.National Pharmacopoeia Committee. Chinese Pharmacopoeia. Beijing, China: China Medical Science Press; 2010. [Google Scholar]
  • 3.Han X., Wu C. A., Wang W., Liu S., Wang L. Y. Mechanism research of stilbene glucoside from Polygonum multiflovum thunb on hyperlipemia. Chinese Archives of Traditional Chinese Medicine. 2008;26(8):1687–1689. [Google Scholar]
  • 4.Gao X., Hu Y.-J., Fu L.-C. Blood lipid-regulation of stilbene glycoside from Polygonum multiflorum . Zhongguo Zhongyao Zazhi. 2007;32(4):323–326. [PubMed] [Google Scholar]
  • 5.Cui H. H., Tian Y., Long S. Y. The effective mechanism of 2, 3, 5, 4′-tetrahy-droxystilbene-2-O-β-D- glucoside in anti-atherosclerosis. Progress in Modern Biomedicine. 2009;9(20):3968–3982. [Google Scholar]
  • 6.Jin W. J. Experimental Study on Concentrated Processed Fleece-Flower Root Decoction in the Treatment of Liver Fibrosis. Dalian, China: Dalian Medical University; 2004. [Google Scholar]
  • 7.Yang Y. Y., Wang H. S., Yang S. B. The clinical effect of treated nonalcoholic fatty liver disease. Chinese Journal of Modern Drug Application. 2012;7(5):66–71. [Google Scholar]
  • 8.Wei X. Y., Zhang J. K., Luo Y. H., Chen S. B., Sun J. L. Antagonistic effect of Astragalus mongholicus and Polygonum multiflorum on thymocytes apoptosis induced by cyclophosphamide. Journal of China Pharmaceutical University. 2000;31(1):35–38. [Google Scholar]
  • 9.Ge C. L., Liu Y. Polysaccharide from Polygonum multiflorum Thunb potentiates the immunological function in immunosuppressed mice. Chinese Journal of New Drugs. 2007;16(24):2040–2042. [Google Scholar]
  • 10.Kim H. N., Kim Y. R., Jang J. Y., et al. Neuroprotective effects of Polygonum multiflorum extract against glutamate-induced oxidative toxicity in HT22 hippocampal cells. Journal of Ethnopharmacology. 2013;150(1):108–115. doi: 10.1016/j.jep.2013.08.014. [DOI] [PubMed] [Google Scholar]
  • 11.Liu L., Li L., Zhao L., Zhang L., Li Y.-L., Ye C.-F. Effects of 2,3,5,4′-tetrahydroxystilbene-2-O-β-D-glucoside on learning and memory abilities of rats with chronic cerebral ischemia. Chinese Journal of Pharmacology and Toxicology. 2008;22(2):108–115. [Google Scholar]
  • 12.Yu J., Xie J., Mao X.-J., et al. Comparison of laxative and antioxidant activities of raw, processed and fermented Polygoni multiflori Radix. Chinese Journal of Natural Medicines. 2012;10(1):63–67. doi: 10.1016/S1875-5364(12)60014-4. [DOI] [PubMed] [Google Scholar]
  • 13.Zhou X. X. Study of High Purity Tetrahydroxystilbene Glucoside's Anti-Aging Effect and the Possible Mechanism. Xi'an, China: Fourth Military Medical University; 2013. [Google Scholar]
  • 14.Zhang L., Yang X., Deng Y. Evaluation and consideration on safety information abroad of Polygonum multiflorum and its preparations. Zhongguo Zhongyao Zazhi. 2009;34(18):2414–2418. [PubMed] [Google Scholar]
  • 15.Shen G. Q., Jiang L., Gong C. Y. Polygonum multiflorum-induced hepatic lesion: retrospective analysis and clinical monitoring. Evaluation and Analysis of Drug-Use in Hospitals of China. 2010;10(11):1040–1042. [Google Scholar]
  • 16.Lao L., Hamilton G. R., Fu J., Berman B. M. Is acupuncture safe? A systematic review of case reports. Alternative Therapies in Health and Medicine. 2003;9(1):72–83. [PubMed] [Google Scholar]
  • 17.Lian X., Ke T. T., Hu A. R. Clinical analysis of 52 cases of drug-induced liver injury caused by Polygonum multiflorum and its preparations. Chinese Archives of Traditional Chinese Medicine. 2013;31(5):1133–1134. [PubMed] [Google Scholar]
  • 18.Zhang Y., Chen S., Lu L. Clinical analysis of 36 cases of drug-induced liver injury by Polygonum multiflorum Thunb. Hainan Medical Journal. 2013;24(2):235–237. [Google Scholar]
  • 19.Chen S. X., Fan P., He W. X., Jiang J., Xiong Z. Y. Clinical Analysis of drug-induced liver injury caused by Polygonum multiflorum . Chinese Journal of Digestion and Medical Imageology. 2012;2(5):266–268. [Google Scholar]
  • 20.Liu G. Q. Clinical analysis of 9 cases of drug-induced liver injury by Polygonum multiflorum Thunb. Contemporary Medicine. 2009;15(30):p. 149. [Google Scholar]
  • 21.Zhou X. H., Qiu X. Clinical analysis of 11 cases of drug-induced liver injury by Polygonum multiflorum Thunb. Journal of North Sichuan Medical College. 2005;20(1):107–108. [Google Scholar]
  • 22.Dong H., Slain D., Cheng J., Ma W., Liang W. Eighteen cases of liver injury following ingestion of Polygonum multiflorum . Complementary Therapies in Medicine. 2014;22(1):70–74. doi: 10.1016/j.ctim.2013.12.008. [DOI] [PubMed] [Google Scholar]
  • 23.Xu J., Wang M. R., He C. L., Sui Y. H., Qiao F. Liver injury by peroral Polygonum multiflorum: an analysis of 40 cases. Military Medical Journal of Southeast China. 2009;11(3):209–210. [Google Scholar]
  • 24.Zhang S. G., Yi W., Hao R. J., Peng J. F., Zhao G. Analysis of 13 cases of liver damage caused by Polygonum multiflorum and its preparations. People's Military Surgeon. 2013;56(6):699–700. [Google Scholar]
  • 25.Jung K. A., Min H. J., Yoo S. S., et al. Drug-induced liver injury: twenty five cases of acute hepatitis following ingestion of Polygonum multiflorum thunb. Gut and Liver. 2011;5(4):493–499. doi: 10.5009/gnl.2011.5.4.493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Ding E. Clinical analysis on the treatment of drug-induced liver injury by Polygonum multiflorum Thunb with magnesium isoglycyrrhizinate. Inner Mongol Journal of Traditional Chinese Medicine. 2012;31(11):15–16. [Google Scholar]
  • 27.Xie X. J., Ma K. F., Liu Y. Analysis of liver injury induced by Polygoni multiflori Radix. Drug Evaluation. 2012;9(32):36–38. [Google Scholar]
  • 28.Guo X. Q. Clinical characteristics analysis of liver damage caused by Polygonum multiflorum . Chinese Community Doctors. 2012;14(4):p. 416. [Google Scholar]
  • 29.Song L. Y. Correlation analysis of drug-induced liver injury caused by Polygonum multiflorum Thunb. Medical Journal of West China. 2011;23(7):1300–1301. [Google Scholar]
  • 30.Wang Y. Clinical research of drug-induced liver injury caused by Polygonum multiflorum . Medical Innovation of China. 2011;8(30):104–105. [Google Scholar]
  • 31.Zhang X., Ding X. C., Yang Y., Zhang P., Wu F. F. Clinical analysis of 6 patients with liver diease induced Polygonum multiflorum Thunb. Journal of Ningxia Medical College. 2000;22(2):115–116. [Google Scholar]
  • 32.Leng M. One case of acute severe liver injury caused by conventional dose Polygonum multiflorum. Journal of Henan Medical College for Staff and Workers. 2002;14(3):p. 277. [Google Scholar]
  • 33.Sheng J. Q. Familial acute liver injury caused by Polygonum multiflorum . Chinese Journal of Hepatology. 1998;6(1):p. 59. [Google Scholar]
  • 34.Ye Q. H. One case of acute toxic liver disease caused by Polygonum multiflorum . Chinese Journal of Integrated Traditional and Western Medicine. 1996;16(12):p. 732. [Google Scholar]
  • 35.Huang W., Zhang Y. N., Sun R. Experimental study on the “Dose-Time-Toxicity” relationship of acute hepatotoxicity induced by different components from Polygonum multiflorum in mice. Chinese Journal of Pharmacovigilance. 2011;8(4):193–197. [Google Scholar]
  • 36.Yu J., Xie J., Zhao R.-H., Cai S.-Q., Chen Z. Advances in studies on liver adverse reaction of Polygonum multiflorum . Chinese Traditional and Herbal Drugs. 2010;41(7):1206–1210. [Google Scholar]
  • 37.Noda T., Yamada T., Ohkubo T., et al. Hot-water-extracts of Polygonum multiflorum do not induce any toxicity but elicit limited beneficial effects on the liver in mice. Journal of Health Science. 2009;55(5):720–725. doi: 10.1248/jhs.55.720. [DOI] [Google Scholar]
  • 38.Liu Y. D., Huang X. X., Wu L. S., Sun D. M., Lu D. Y. Experimental study of liver toxicity of Polygonum multiflorum Thunb. Asia-Pacific Traditional Medicine. 2007;3(4):71–72. [Google Scholar]
  • 39.Zhou S. K., Wu L. D. Analysis and preventive measures of adverse reaction of Chinese herbal medicine. Chinese Journal of Ethnomedicine and Ethnopharmacy. 2013;(12):43–44. [Google Scholar]
  • 40.Guo C. J. Analysis of the causes of adverse reaction of traditional Chinese medicine decoction and recommendations. Information on Traditional Chinese Medicine. 2013;20(3):168–170. [Google Scholar]
  • 41.Sun X. H., Ji H. S., Han J. X., Wang L. P. Focus on the ADR charicteristics of traditional Chinese herbal medicine and its prevent measures from the liver damage by Poligoni multiflori radix. Guide of China Medicine. 2010;18(34):21–22. [Google Scholar]
  • 42.Liu H. P., Wu X. R., Yuan J. Hepatic damage and agranulocytosis due to Polygonum multiflorum . Adverse Drug Reactions Journal. 2013;15(5):298–300. [Google Scholar]
  • 43.Miao Y. J., Yun Y. L. Two cases of drug-induced hepatitis caused by Polygonum multiflorum . Chinese Journal of Drug Application and Monitoring. 2013;10(1):61–62. [Google Scholar]
  • 44.Zhao G. X. One case of hepatitis caused by Jin-Wu-Pian. Inner Mongol Journal of Traditional Chinese Medicine. 2013;32(10):180–181. [Google Scholar]
  • 45.Tan S. Pharmaceutical care one case of drug-induced hepatitis caused by Polygonum multiflorum . Proceedings of the 9th Clinical Pharmacist Forum; 2013. [Google Scholar]
  • 46.Liu Z Y., Hu Z. B., Wang X. F. Processed Polygonum multiflorum induced one case liver damage and literature review. Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases. 2013;23(3):176–177. [Google Scholar]
  • 47.Gao Y., Jia L., Yu K. J. Polygoni multiflori Radix praeparata and Tribuli fructus induced acute liver failure. Adverse Drug Reactions Journal. 2013;15(5):294–295. [Google Scholar]
  • 48.Baňárová A., Koller T., Payer J. Toxic hepatitis induced by Polygonum multiflorum . Vnitr˘ní lékar˘ství. 2012;58(12):958–962. [PubMed] [Google Scholar]
  • 49.Gao L. S. One case of drug-induced hepatitis caused by Polygonum multiflorum . Health Must Read. 2012;11(10):p. 576. [Google Scholar]
  • 50.Kui X. H., Chen X. Q. One case of drug-induced hepatitis caused by Polygonum multiflorum combination a variety of cold medicine. Chinese Medicine. 2012;7(2):p. 241. [Google Scholar]
  • 51.Shao Y. L., Li Q. Two cases of drug-induced hepatitis caused by Polygonum multiflorum . Journal of Qilu Nursing. 2012;18(22):p. 111. [Google Scholar]
  • 52.Hu Y. C., Li H. Z., Chen R. L. One case of drug-induced hepatitis caused by Polygonum multiflorum . Herald of Medicine. 2012;31(4):p. 542. [Google Scholar]
  • 53.Zhen L. X., Zeng C. Z. One case of drug-induced hepatitis caused by Polygonum multiflorum . Chinese Joumal of Ethnomedieine and Ethnopharmacy. 2012;(21):p. 50. [Google Scholar]
  • 54.Li Z. X., Zhang Z. Two cases of icteric viral hepatitis caused by unprocessed Polygonum multiflorum . Chinese Journal of Aesthetic Medicine. 2012;21(12):p. 775. [Google Scholar]
  • 55.Chen S. P., Tan F. M., Yang Y. Y. One case of acute hepatitis caused by Polygonum multiflorum. Chinese Hepatology. 2012;17(1):p. 68. [Google Scholar]
  • 56.Liu S. M., Tang Y. P., Gong Y. X. One case of acute hepatitis caused by Yishen wufa. Chinese Journal of Integrated Traditional and Western Medicine on Digestion. 2012;20(4):p. 182. [Google Scholar]
  • 57.Sun S. M. Two cases of liver damage caused by Polygonum multiflorum . Guide of China Medicine. 2011;9(26):136–137. [Google Scholar]
  • 58.Cao M. X., Liu M., Wu R. R., Liu F. Q., Zhou X. One case of liver damage caused by processed Polygonum multiflorum . Chinese Journal of Pharmacovigilance. 2011;8(8):p. 510. [Google Scholar]
  • 59.Liu Y., Chen W. Y., Zhao Y. Q., Xiang H. One case of drug-induced hepatitis caused by Shengfa Yangxue Capsule. Journal of Military Surgeon in Southwest China. 2011;13(6):p. 1011. [Google Scholar]
  • 60.Yan Y. Q. One case of liver damage caused by long-term low-dose administration of Polygonum multiflorum . Medical Journal of Beijing Military Region. 2011;23(5):p. 41. [Google Scholar]
  • 61.Wu Z. Q., Niu H. Y. One case of severe liver damage caused by Polygonum multiflorum . World Health Digest Medical Periodieal. 2011;8(12):414–415. [Google Scholar]
  • 62.Liu W. Z., Teng Y. M., Lei L. One case of acute liver injury caused by Shou-Wu-Wan. Journal of Shantou University Medical College. 2010;23(3):p. 172. [Google Scholar]
  • 63.Chen M. X., Chen X. Y., Tang W. Two cases of drug-induced hepatitis caused by Polygonum multiflorum . Sichuan Medical Journal. 2010;31(9):1390–1391. [Google Scholar]
  • 64.Yun D. W., Guo X. R., Gao X. F. One case of liver injury caused by Shou-Wu-Wan. Chinese Journal of Coal Industry Medicine. 2010;13(7):p. 1084. [Google Scholar]
  • 65.Furukawa M., Kasajima S., Nakamura Y., et al. Toxic hepatitis induced by Show-Wu-Pian, a Chinese herbal preparation. Internal Medicine. 2010;49(15):1537–1540. doi: 10.2169/internalmedicine.49.3509. [DOI] [PubMed] [Google Scholar]
  • 66.Yan X. Y., Meng Q. C., Yan Z. S. One case of liver damage caused by Polygonum multiflorum . Chinese Journal of Difficult and Complicated Cases. 2009;8(7):p. 399. [Google Scholar]
  • 67.He R. One case of liver damage caused by Polygonum multiflorum after postpartum. Medical Journal of West China. 2009;21(5):p. 774. [Google Scholar]
  • 68.Chen X. Y. Plasmapheresis combined with hemofiltration treatment one case drug-induced hepatitis caused by Polygonum multiflorum . Journal of Emergency in Traditional Chinese Medicine. 2009;18(5):824–826. [Google Scholar]
  • 69.Cho H. C., Min H. J., Ha C. Y., et al. Reactivation of Pulmonary tuberculosis in a patient with Polygonum multiflorum Thunb-Induced hepatitis. Gut and Liver. 2009;3(1):52–56. doi: 10.5009/gnl.2009.3.1.52. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Wang F. F., Jin C. H., Guan M. Three cases of hepatitis caused by Polygonum multiflorum . West China Medical Journal. 2008;23(3):p. 631. [Google Scholar]
  • 71.Zhu B. S. One case of drug-induced hepatitis caused by Polygonum multiflorum. Journal of Huaihai Medicine. 2008;26(4):p. 320. [Google Scholar]
  • 72.Yang J., Li Z. G. Two cases of drug-induced hepatitis caused by Polygonum multiflorum . Shanxi Medical Journal. 2008;37(11):p. 973. [Google Scholar]
  • 73.Laird A. R., Ramchandani N., Degoma E. M., Avula B., Khan I. A., Gesundheit N. Acute hepatitis associated with the use of an herbal supplement (Polygonum multiflorum) mimicking iron-overload syndrome. Journal of Clinical Gastroenterology. 2008;42(7):861–862. doi: 10.1097/mcg.0b013e3181492515. [DOI] [PubMed] [Google Scholar]
  • 74.Yang J. L., Dong Y. J. Two cases of liver damage caused by Shou-Wu-Pian. Journal of the Fourth Military Medical University. 2007;28(2):p. 162. [Google Scholar]
  • 75.Fu P., Yu Y. One case of hepatitis caused by Polygonum multiflorum . China's Naturopathy. 2007;15(3):p. 41. [Google Scholar]
  • 76.Zhao X. D. One case of acute liver injury caused by Shou-Wu-Wan. Zhongguo Zhongyao Zazhi. 2007;32(5):p. 444. [Google Scholar]
  • 77.Li Z. Two cases of liver damage caused by Polygonum multiflorum . Chinese Journal of Misdiagnostics. 2006;6(10):p. 2033. [Google Scholar]
  • 78.Cárdenas A., Restrepo J. C., Sierra F., Correa G. Acute hepatitis due to Shen-Min: a herbal product derived from Polygonum multiflorum . Journal of Clinical Gastroenterology. 2006;40(7):629–632. doi: 10.1097/00004836-200608000-00014. [DOI] [PubMed] [Google Scholar]
  • 79.Han J. L. Hepatitis attributed to Radix Polygoni multiflori . Adverse Drug Reactions Journal. 2006;8(5):p. 390. [Google Scholar]
  • 80.Yang D. Q. Polygonum cause severe liver damage. Adverse Drug Reactions Journal. 2005;(6):p. 449. [Google Scholar]
  • 81.Panis B., Wong D. R., Hooymans P. M., De Smet P. A. G. M., Rosias P. P. R. Recurrent toxic hepatitis in a Caucasian girl related to the use of Shou-Wu-Pian, a Chinese herbal preparation. Journal of Pediatric Gastroenterology and Nutrition. 2005;41(2):256–258. doi: 10.1097/01.MPG.0000164699.41282.67. [DOI] [PubMed] [Google Scholar]
  • 82.Chen C., Zhao C. J., Yu X. Z. One case of liver damage caused by Polygonum multiflorum . Anhui Medical and Pharmaceutical Journal. 2005;9(3):p. 204. [Google Scholar]
  • 83.Huo M. Y., Ling S. H. Hepatitis due to the concomitant administration of Shou-Wu-Pian and Yangxue Shengfa capsules. Adverse Drug Reactions Journal. 2004;(5):335–336. [Google Scholar]
  • 84.Mazzanti G., Battinelli L., Daniele C., et al. New case of acute hepatitis following the consumption of Shou Wu Pian, a Chinese herbal product derived from Polygonum multiflorum . Annals of Internal Medicine. 2004;140(7):p. 30. doi: 10.7326/0003-4819-140-7-200404060-00042-w3. [DOI] [PubMed] [Google Scholar]
  • 85.Shao Z. Y. Two cases of liver damage caused by Polygonum multiflorum . Zhejiang Journal of Integrated Traditional Chinese and Western Medicine. 2003;13(11):716–718. [Google Scholar]
  • 86.Dai S. Q., Li Y. M. One case of liver damage caused by Polygonum multiflorum . Ningxia Medical Journal. 2002;24(8):p. 501. [Google Scholar]
  • 87.Yuan W. D. One case of acute liver injury caused by Polygonum multiflorum . Chinese Remedies & Clinics. 2002;2(6):p. 416. [Google Scholar]
  • 88.Sun J. One case of severe liver damage caused by Chinese drugs for invigoration. Chinese Journal of Integrated Traditional and Western Medicine on Digestion. 2002;10(5):p. 292. [Google Scholar]
  • 89.Yang J. Y. One case of liver damage caused by Polygonum multiflorum . Turpan Science and Technology. 2002;(4):50–51. [Google Scholar]
  • 90.Park G. J.-H., Mann S. P., Ngu M. C. Acute hepatitis induced by Shou-Wu-Pian, a herbal product derived from Polygonum multiflorum. Journal of Gastroenterology and Hepatology. 2001;16(1):115–117. doi: 10.1046/j.1440-1746.2001.02309.x. [DOI] [PubMed] [Google Scholar]
  • 91.Li Z. H., Gai D. M., Zhuang X. R. Hepatitis attributed to Polygonum multiflorum . Shandong Journal of Traditional Chinese Medicine. 1998;17(7):23–24. [Google Scholar]
  • 92.Fan D. M., Zhou Z. L. One case of liver damage caused by Polygonum multiflorum . Journal of Norman Bethune University of Medical Science. 1998;24(3):p. 292. [Google Scholar]
  • 93.Li F. X. One case of liver injury caused by Shou-Wu-Wan. Journal of New Chinese Medicine. 1997;29(12):42–43. [Google Scholar]
  • 94.Zhang W. F. One case of liver injury caused by Huo-Li-Su. Journal of Practical Traditional Chinese Medicine. 1997;13(2):p. 41. [Google Scholar]
  • 95.Niu J. H. One case of severe liver damage caused by Shou-Wu-Pian. New Drugs and Clinical Remedies. 1996;15(6):p. 63. [Google Scholar]
  • 96.He M. H., Zhen X. J. Two cases of acute liver damage caused by Polygonum multiflorum . Shanxi Journal of Traditional Chinese Medicine. 1996;17(5):p. 230. [Google Scholar]
  • 97.But P. P.-H., Tomlinson B., Lee K.-L. Hepatitis related to the Chinese medicine Shou-Wu-Pian manufactured from Polygonum multiflorum . Veterinary and Human Toxicology. 1996;38(4):280–282. [PubMed] [Google Scholar]
  • 98.Liu F., Li Z. Analysis of 7 cases of drug-induced liver injury by Polygonum multiflorum . Inner Mongol Journal of Traditional Chinese Medicine. 2010;29(6):p. 58. [Google Scholar]
  • 99.Yang X. X., Jiang N., Lin J. M. Clinical analysis of 13 patients with liver diease induced Polygonum multiflorum Thunb. Sichuan Medical Journal. 2008;29(12):1619–1620. [Google Scholar]

Articles from Evidence-based Complementary and Alternative Medicine : eCAM are provided here courtesy of Wiley

RESOURCES